LB Pharmaceuticals (LBRX) news
Recent news
LB Pharmaceuticals Inc: H.C. Wainwright raises target price to $60 from $45
H.C. Wainwright & Co. has revised its price target for LB Pharmaceuticals Inc (NASDAQ: LBPH), raising it to $60 from $45, reflecting a positive reassessment of the company’s outlook. The adjustment follows recent developments in the company’s pipeline and strategic initiatives, which the firm…
AInvest Wire · 7d agoLB Pharmaceuticals - net proceeds to fund LB-102 pipeline expansion and general corporate purposes
AInvest Wire · Jul 29, 2026LB Pharmaceuticals announces $150 million private placement
AInvest Wire · Jul 29, 2026LB Pharma: expects to report topline from Phase 3 Nova-2 in 1H 2027
LB Pharmaceuticals has initiated its pivotal Phase 3 NOVA-2 trial to evaluate LB-102 as a treatment for schizophrenia . The trial is a multi-center, randomized, double-blind, placebo-controlled study enrolling approximately 460 participants with acute exacerbation of schizophrenia across 25 U.S.…
AInvest Wire · Jul 22, 2026LB Pharmaceuticals reports inducement grant to new employee under Nasdaq listing Rule 5635(c)(4)
AInvest Wire · Jul 10, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.